reviewJournal of NeurologySep 7, 2023HYBRID OA

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

TKTania KümpfelKGKatrin GiglhuberOAOrhan AktaşIAIlya AyzenbergJBJudith Bellmann–Strobl

Ludwig-Maximilians-Universität München · TUM Klinikum · +28 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized…

Citation impact

222
total citations
FWCI
52.45
Percentile
100%
References
256
Citations per year

Authors

140

Topics & keywords

Topics
Keywords
  • Neuromyelitis optica
  • Medicine
  • Rituximab
  • Eculizumab
  • Disease
  • Spectrum disorder
  • Immunology
  • Intensive care medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding